All Stories

  1. DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

    Article • Vascular Health and Risk Management, March 2017, Dove Medical Press

    Dr James E Foley

  2. Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus

    Article • Vascular Health and Risk Management, August 2016, Dove Medical Press

    Dr James E Foley

  3. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?

    Article • Vascular Health and Risk Management, January 2016, Dove Medical Press

    Dr James E Foley

  4. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

    Article • Vascular Health and Risk Management, November 2014, Taylor & Francis

    Dr James E Foley, giovanni bader

  5. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

    Article • Vascular Health and Risk Management, February 2013, Taylor & Francis

    Dr James E Foley

  6. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

    Article • Vascular Health and Risk Management, January 2013, Taylor & Francis

    Dr James E Foley

  7. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

    Article • Vascular Health and Risk Management, May 2012, Taylor & Francis

    Dr James E Foley, Dr Sylvie Dejager

  8. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

    Article • Vascular Health and Risk Management, February 2011, Taylor & Francis

    Dr James E Foley, Dr Sylvie Dejager

  9. Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

    Article • Vascular Health and Risk Management, July 2010, Taylor & Francis

    Dr James E Foley